Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
Eduardo Rodríguez-Arbolí,Megan Othus,Sylvie D. Freeman,Francesco Buccisano,Lok Lam Ngai,Ian Thomas,Raffaele Palmieri,Jacqueline Cloos,Sean Johnson,Elisa Meddi,Nigel H. Russell,Adriano Venditti,Patrycja Gradowska,Gert J. Ossenkoppele,Bob Löwenberg,Roland B. Walter
DOI: https://doi.org/10.1038/s41375-024-02378-5
2024-08-23
Leukemia
Abstract:Multiparameter flow cytometry (MFC)-based MRD testing is increasingly utilized in AML, but methodologies and assay characteristics vary substantially [1,2,3]. Nonetheless, following regulatory authorities' guidance MRD assays be validated 1-log below the chosen threshold for clinical decision-making, the European LeukemiaNet (ELN) MRD Working Party presently defines MRD positivity uniformly at 0.1% [2]. Yet, agnostic to assay specifications, risk stratification may be suboptimal. We examined this possibility using 4 well-annotated cohorts of AML patients in morphologic remission in which MRD results did not guide treatment decisions. Our dataset included patients from GIMEMA ( n = 182, from EORTC/GIMEMA AML-10 and AML-12), HOVON/SAKK ( n = 171, from HOVON/SAKK 42A), MRC/NCRI ( n = 846, from AML17), and Seattle ( n = 861; adults allografted in first morphologic remission). All patients were treated on IRB-approved research protocols or standard treatment protocols and gave consent in accordance with the Declaration of Helsinki; for details, see online supplement. For GIMEMA, cases expressing a leukemia-associated immunophenotype (LAIP) were re-analyzed with a combination of 6–8 markers to define a LAIP fingerprint for MRD tracking [4,5,6,7]. For HOVON/SAKK, a suitable LAIP comprising ≥10% of the CD45 dim blasts was identified at diagnosis using a 4-color assay and monitored during follow-up. For MRC/NCRI, MFC-MRD testing was centrally performed with a standardized 7/8-color assay that screened for "different-from-normal" LAIPs pretreatment and tracked these ( ∼ 0.02–0.05% sensitivity) but also applied the different-from-normal approach in follow-up samples to detect LAIP changes ( ∼ 0.05–0.1% sensitivity). Only samples with pretreatment LAIPs could be reported as MRD neg . For Seattle, pre-transplant bone marrows were subjected to 10-color MFC-MRD testing with a panel of 3 antibody combinations, collecting up to 1 million events/tube [8, 9]. MRD was identified using a "different-from-normal" approach, with detection sensitivity to a level of 0.1% in most cases and at lower levels in progressively smaller patients subsets [8, 9]. For all cohorts, only samples of sufficient quality for MRD testing were included in our analyses, which were conducted under a research protocol approved by the Fred Hutchinson Cancer Center's Institutional Review Board.
oncology,hematology